Stanza
Commercial- Indications
- Fibromyalgia
Company intelligence / Profile preview
Stanza demonstrated statistically significant and clinically meaningful improvements in wellbeing, fibromyalgia severity, and major symptoms associated with fibromyalgia—including pain intensity, fatigue, sleep disturbance, depression—without treatment-related safety events. The pivotal PROSPER-FM Phase 3 randomized controlled trial was the largest RCT undertaken on fibromyalgia treatment devices. Stanza received FDA De Novo marketing authorization in May 2023.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Swing Therapeutics.